XML 20 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Jun. 30, 2018
Jul. 01, 2017
Cash Flows from Operating Activities:    
Net (loss) income $ (2,819) $ 20,137
Non-cash items:    
Depreciation and amortization 26,415 21,789
Gain on divestiture 0 (8,000)
Stock-based compensation expense 3,379 1,343
Impairment of assets 21,170 0
Provision for losses on accounts receivable and inventory (352) 928
Other non-cash operating activities 19 658
Change in operating assets and liabilities:    
Change in accounts receivable (1,577) 2,203
Change in inventories (15,058) 1,417
Change in prepaid income taxes 72 817
Change in other assets and other liabilities (1,214) 8,998
Change in accounts payable and accrued expenses (6,913) (11,865)
Net cash provided by operating activities 23,122 38,425
Cash Flows from Investing Activities:    
Capital expenditures (27,514) (13,721)
Proceeds from divestiture 0 9,000
Proceeds from sale of property, plant and equipment 250 981
Net cash used in investing activities (27,264) (3,740)
Cash Flows from Financing Activities:    
Term loan borrowings 347,780 0
Term loan borrowings (253,728) (11,856)
Proceeds from employee stock purchase plan 1,780 1,622
Proceeds from exercise of stock options 2,831 6,430
Share repurchases (80,000) 0
Net increase in short-term loans 0 255
Net cash provided by (used in) financing activities 18,663 (3,549)
Effect of exchange rates on cash and cash equivalents (2,584) 1,039
Net Change in Cash and Cash Equivalents 11,937 32,175
Cash and Cash Equivalents at Beginning of Period 180,169 139,564
Cash and Cash Equivalents at End of Period 192,106 171,739
Supplemental Disclosures of Cash Flow Information:    
Interest paid 2,361 1,825
Income taxes paid 1,817 2,151
Transfers from inventory to fixed assets for placement of Haemonetics equipment $ 1,799 $ 1,338